Biomarkers and Surrogate End points in Multiple Sclerosis Trials: Regulatory Issues

Overview of attention for article published in Journal of clinical neurophysiology, June 2020

Altmetric Badge

About this Attention Score

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 4,001 followers.

Biomarkers and Surrogate End points in #MultipleSclerosis Trials: Regulatory issues by @markskeen @DukeU @dukemedicine & @luca__pani -https://t.co/nPMH44y2EQ @ACNS_org @JClinNeurophys

New article: Biomarkers and Surrogate End points in Multiple Sclerosis Trials: Regulatory Issues https://t.co/mFP1yPUpLv #MS #multiplesclerosis #neurology https://t.co/69mkM8TJ5R

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.